Video

Dr. Xiu on HR Expression in Uterine Carcinosarcoma

Author(s):

Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

A study led by Xiu demonstrated that HR is overexpressed in a small subset of patients with uterine carcinosarcoma. Hormonal therapies have not been tested within this tumor type, Xiu explains. This prompts a thought that, following other treatment options, oncologists could consider hormonal therapies for patients.

Moreover, researchers saw the PI3K mTOR pathway activated, suggesting that oncologists could consider a combination of hormonal and targeted therapies. This is something to be tested in clinical trials, Xiu adds.

PD-1/PD-L1 expression was also found in this patient subset.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
Dr Sullivan on RP1 Plus Nivolumab in Anti–PD-1–Refractory Melanoma
Neeta Somaiah, MD
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Omid Hamid, MD
Marlana M. Orloff, MD